Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H16O4 |
Molecular Weight | 308.3279 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C=C1)\C=C\C(=O)CC(=O)\C=C\C2=CC=C(O)C=C2
InChI
InChIKey=PREBVFJICNPEKM-YDWXAUTNSA-N
InChI=1S/C19H16O4/c20-16-7-1-14(2-8-16)5-11-18(22)13-19(23)12-6-15-3-9-17(21)10-4-15/h1-12,20-21H,13H2/b11-5+,12-6+
Molecular Formula | C19H16O4 |
Molecular Weight | 308.3279 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28075008Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23873854 | https://www.ncbi.nlm.nih.gov/pubmed/26546528 | https://www.ncbi.nlm.nih.gov/pubmed/26546528 | https://www.ncbi.nlm.nih.gov/pubmed/26777574
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28075008
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23873854 | https://www.ncbi.nlm.nih.gov/pubmed/26546528 | https://www.ncbi.nlm.nih.gov/pubmed/26546528 | https://www.ncbi.nlm.nih.gov/pubmed/26777574
Bisdemethoxycurcumin (BDMC) is a minor constituent (approximately 3%) of curcuminoids that has been shown to be more stable than the other two main curcuminoids, that is, curcumin and desmethoxycurcumin. Bisdemethoxycurcumin inhibits the proliferation and survival of several types of tumor cells including colon cancer cells, breast cancer cells, leukemia cells, and glioma cells. In addition, Bisdemethoxycurcumin suppresses cancer invasion and has the highest anti-metastatic potency in HT1080 human fibrosarcoma cells among the three curcuminoids. Bisdemethoxycurcumin has been reported to possess anti-oxidant and anti-inflammatory activities. However, the underlying molecular mechanisms responsible for the inhibitory action of Bisdemethoxycurcumin on tumor invasion and migration have remained largely unknown. More interestingly, the anti-cancer effects of Bisdemethoxycurcumin are comparable to and sometimes more potent than those of curcumin in different conditions.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0016055 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28075008 |
|||
Target ID: WP2824 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28075008 |
|||
Target ID: WP2902 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28075008 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. | 1997 Sep 12 |
|
Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. | 2005 Feb 23 |
|
Inhibition of multidrug resistance proteins MRP1 and MRP2 by a series of alpha,beta-unsaturated carbonyl compounds. | 2005 Jun 15 |
|
Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). | 2006 Feb |
|
Regulation of heme oxygenase-1 expression by demethoxy curcuminoids through Nrf2 by a PI3-kinase/Akt-mediated pathway in mouse beta-cells. | 2007 Sep |
|
Comparison of suppressive effects of demethoxycurcumin and bisdemethoxycurcumin on expressions of inflammatory mediators in vitro and in vivo. | 2008 Apr |
|
Immune defects in Alzheimer's disease: new medications development. | 2008 Dec 3 |
|
Comparison of inhibitory potency of three different curcuminoid pigments on nitric oxide and tumor necrosis factor production of rat primary microglia induced by lipopolysaccharide. | 2008 Dec 5 |
|
Dimethoxycurcumin, a synthetic curcumin analogue with higher metabolic stability, inhibits NO production, inducible NO synthase expression and NF-kappaB activation in RAW264.7 macrophages activated with LPS. | 2008 Sep |
|
Effect of pure curcumin, demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines. | 2008 Sep |
|
Comparative antiulcer effect of bisdemethoxycurcumin and curcumin in a gastric ulcer model system. | 2009 Apr |
|
Optimized turmeric extracts have potent anti-amyloidogenic effects. | 2009 Dec |
|
Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. | 2009 Feb |
|
Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA. | 2009 Feb |
|
Induction of antioxidant enzymes by curcumin and its analogues in human islets: implications in transplantation. | 2009 May |
|
Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. | 2010 Oct |
|
Evaluation in vitro of synthetic curcumins as agents promoting monocytic gene expression related to β-amyloid clearance. | 2012 Jan 13 |
|
Curcuminoids distinctly exhibit antioxidant activities and regulate expression of scavenger receptors and heme oxygenase-1. | 2013 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26777574
Mice were treated with Bisdemethoxycurcumin as a dose of either 1 or 5 g/kg diet for 15 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26546528
NCI-H460 cells at a density of 5Ч105 cells/ml were maintained on 12-well plates with RPMI-1640 medium for 24 h and then incubated with or without 35 μM of Bisdemethoxycurcumin for 24 h. At the end of incubation, cells were collected from each treatment and total RNA was extracted by using the Qiagen RNeasy Mini Kit (Qiagen, Inc, Valencia, CA, USA)
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:42:25 GMT 2023
by
admin
on
Fri Dec 15 15:42:25 GMT 2023
|
Record UNII |
2EFO1BP34R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
3710 (Number of products:81)
Created by
admin on Fri Dec 15 15:42:25 GMT 2023 , Edited by admin on Fri Dec 15 15:42:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000009705
Created by
admin on Fri Dec 15 15:42:25 GMT 2023 , Edited by admin on Fri Dec 15 15:42:25 GMT 2023
|
PRIMARY | |||
|
2EFO1BP34R
Created by
admin on Fri Dec 15 15:42:25 GMT 2023 , Edited by admin on Fri Dec 15 15:42:25 GMT 2023
|
PRIMARY | |||
|
DTXSID00872663
Created by
admin on Fri Dec 15 15:42:25 GMT 2023 , Edited by admin on Fri Dec 15 15:42:25 GMT 2023
|
PRIMARY | |||
|
71045
Created by
admin on Fri Dec 15 15:42:25 GMT 2023 , Edited by admin on Fri Dec 15 15:42:25 GMT 2023
|
PRIMARY | |||
|
33171-05-0
Created by
admin on Fri Dec 15 15:42:25 GMT 2023 , Edited by admin on Fri Dec 15 15:42:25 GMT 2023
|
PRIMARY | |||
|
5315472
Created by
admin on Fri Dec 15 15:42:25 GMT 2023 , Edited by admin on Fri Dec 15 15:42:25 GMT 2023
|
PRIMARY | |||
|
Curcumin III
Created by
admin on Fri Dec 15 15:42:25 GMT 2023 , Edited by admin on Fri Dec 15 15:42:25 GMT 2023
|
PRIMARY | |||
|
1075305
Created by
admin on Fri Dec 15 15:42:25 GMT 2023 , Edited by admin on Fri Dec 15 15:42:25 GMT 2023
|
PRIMARY |